EP Patent

EP1313736B1 — Condensed pyrazindione derivatives as inhibitors of pde5

Assigned to Lilly Icos LLC · Expires 2005-07-27 · 21y expired

What this patent protects

Compounds of the general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents.

USPTO Abstract

Compounds of the general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents.

Drugs covered by this patent

pexidartinib-hydrochloride (PEXIDARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: EP1313736B1
Jurisdiction: EP
Classification: —
Expires: 2005-07-27
Drug substance claim: No
Drug product claim: No
Assignee: Lilly Icos LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.